Clover Health Investments, Corp.(CLOV)Earnings, Financials & Key RatiosClover Health Investments, Corp. (CLOV) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company achieved a positive $107.9M in operating cash flow during 2026Q1, the reliance on significant stock-based compensation and the historical $2.3B accumulated deficit warrant a cautious approach to valuation.
Clover Health Investments, Corp. (CLOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Clover Health Investments, Corp. (CLOV) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.07vs $0.07+0.0% | $749Mvs $715M+4.8% |
| Q1 2026 | Feb 26, 2026 | $0.05vs $0.10+51.0% | $488Mvs $467M+4.4% |
| Q4 2025 | Nov 4, 2025 | $0.05vs $0.02-350.0% | $497Mvs $467M+6.3% |
| Q3 2025 | Aug 5, 2025 | $0.03vs $0.03+0.0% | $478Mvs $468M+2.0% |
Recent stock market news and headlines for Clover Health Investments, Corp. (CLOV)
Director Carladenise Edwards sold 67,160 shares for a transaction value of approximately ~$230,000 on May 18, 2026, at a weighted average price of around $3.42 per share. This sale represented 19% of her direct holdings at the time, reducing direct ownership from 352,592 to 285,432 shares.
Key metrics vs top competitors for Clover Health Investments, Corp. (CLOV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.00 | $2.59B | -29.41 | 40.34% | -4.45% | -26.33% | — | |
| $394.62 | $47.38B | 40.10 | 10.06% | 0.82% | 6.17% | — | |
| $104.33 | $133.12B | 75.06 | 7.85% | 0.72% | 3.86% | — | |
| $418.85 | $90.96B | 16.67 | 12.62% | 2.62% | 11.92% | — | |
| $66.12 | $32.65B | -4.85 | 19.44% | -3.25% | -28.6% | — | |
| $232.90 | $12.13B | 26.11 | 11.75% | 0.42% | 4.44% | — |
Clover Health Investments, Corp. (CLOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Clover Health Investments, Corp. (CLOV) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Apr 1, 2026·SEC
Mar 6, 2026·SEC
Get notified when CLOV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Clover Health Investments, Corp. (CLOV) stock FAQ — growth, dividends, profitability & financials explained
Clover Health Investments, Corp. (CLOV) reported $2.21B in revenue for fiscal year 2025. This represents a 685% increase from $281.0M in 2018.
Clover Health Investments, Corp. (CLOV) grew revenue by 40.3% over the past year. This is strong growth.
Clover Health Investments, Corp. (CLOV) reported a net loss of $56.9M for fiscal year 2025.
Clover Health Investments, Corp. (CLOV) has a return on equity (ROE) of -26.3%. Negative ROE indicates the company is unprofitable.
Clover Health Investments, Corp. (CLOV) generated $54.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
